Skip to main content
. 2019 Nov;96(5):641–654. doi: 10.1124/mol.119.117069

Fig. 1.

Fig. 1.

Strategy for generating the liver-conditional gp78/AMFR-KO mouse model and corresponding validation. (A) Conditional gene trap (cgt) strategy to develop gp78-floxed (gp78f) mice and, subsequently, liver-conditional gp78-KO mice (gp78−). Arrows indicate the sites of the genotyping primers employed. (B and C) PCR genotype analyses of genomic DNA isolated via tail-clipping of mice at various stages of the strategy. See Materials and Methods for experimental details. The primer pairs for each genotyping product and the corresponding amplicon size are indicated. flpF/flpR primers used to verify the amplicon obtained upon Flpe recombinase in WT (+/+); cgt/+, heterozygous with the cgt-cassette insert; and cgt/cgt, homozygous with the cgt-cassette insert. Amplicons verifying WT gp78 (+/+), Alb/Cre, heterozygous gp78-KO (+/−), and Alb-Cre and homozygous gp78-KO (−/−), each Alb-Cre carrying an Alb-Cre allele upon mating with Alb-Cre/Alb-Cre mice. (D) IB analyses of liver and brain lysates from WT and KO mice with a rabbit anti-mouse gp78-antibody, verifying the liver-specific gp78 KO.